Skip to content

Efficacy and safety of non-opioid combined intravenous anesthesia in elderly patients undergoing short daytime surgeries: A randomized controlled trial

Efficacy and safety of non-opioid combined intravenous anesthesia in elderly patients undergoing short daytime surgeries: A randomized controlled trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500102550
Enrollment
Unknown
Registered
2025-05-15
Start date
2025-05-20
Completion date
Unknown
Last updated
2025-05-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adverse reactions to opioids

Interventions

Opioid group:Induction with Succinylcholine 0.2-0.4 ug/kg, Propofol 1.5-2.0 mg/kg, Rocuronium 0.6 mg/kg, maintenance with Remifentanil 0.1-0.2 ug/kg/min and Propofol 2-10 mg/kg/h.
Non-opioid group:Induction with esketamine 0.2-0.4 mg/kg, propofol 1.5-2.0 mg/kg, rocuronium 0.6 mg/kg-1.0 mg/kg, lidocaine 1 mg/kg
maintenance with esketamine 0.1 mg/kg/h, propofol 2-10 mg/kg/h, dexmedetomidine 0.3-1.0 ug/kg/h.

Sponsors

The First Hospital Of Jiaxing
Lead Sponsor

Eligibility

Sex/Gender
All
Age
60 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Short surgery under general anesthesia at our hospital (<90 minutes); 2. Elderly patients over 60 years old; 3. ASA1-3 level 4. General anesthesia patients

Exclusion criteria

Exclusion criteria: 1. Patients undergoing epidural anesthesia; 2. Severe cardiovascular diseases (such as unstable angina and NYHA III-IV heart failure); 3. Severe liver and kidney dysfunction (such as Child Pugh C grade eGFR 9%); 5. Active infection or immunosuppression status; 6. Long term use of opioid drugs before surgery (such as in patients with chronic pain) or a history of opioid dependence; 7. Allergies or contraindications to experimental drugs (such as propofol, dexmedetomidine, ketamine, etc.); 8. Moderate to severe cognitive impairment (such as MMSE score2 hours) or transferred to open surgery; 10. Emergency surgery or combined surgery with other organs; Participate in other clinical trials or refuse to sign informed consent.

Design outcomes

Primary

MeasureTime frame
Composite endpoints for opioid-related adverse events;

Secondary

MeasureTime frame
Length of stay;Intraoperative hemodynamic stability;PACU stay time;Pain score;Extubation time;Whether emergency antiemetic and analgesic drugs are needed;

Countries

China

Contacts

Public ContactHuadong Ni

The First Hospital Of Jiaxing

huadongni@126.com+86 15068386387

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026